Abstract

Pancreatic cancer is a devastating disease with poor survival outcomes. Recent studies have shown that the addition of radiotherapy to chemotherapy in the setting of locally advanced pancreatic cancer did not improve overall survival outcome. These studies commonly utilize conventional radiotherapy treatment fractionation and technique (typically 3-D conformal radiotherapy or intensity modulated radiotherapy). Although no clear benefit in overall survival was demonstrated in those studies, those who received radiotherapy did have a clear benefit in terms of local control. Therefore, there is increasing interest in exploring different techniques and/or modality of radiotherapy and dose/fractionation. Stereotactic radiotherapy, which employs a hypofractionated regimen, has the potential advantage of delivering a high dose of radiation to the tumor in a short period of time (typically over 5 days) with minimal dose to the surrounding normal structures. Particle therapy such as proton and carbon ion therapy are being explored as potential radiation modality that could cause greater biological damage to the tumor compared to photon treatment, with rapid dose falloff resulting in minimal to no dose to adjacent structures. This review will discuss the current literature and emerging roles of stereotactic radiotherapy and particle therapy in pancreatic cancer.

Highlights

  • Pancreatic cancer, being the third leading cause of cancer-related deaths in the United States, is a devastating disease with an estimated 5-year overall survival of only 6% [1]

  • The recent LAP07 study showed no overall survival with chemotherapy alone, as compared to chemoradiotherapy after completion of induction chemotherapy in patients with locally advanced pancreatic cancer (LAPC); the study did demonstrate that those who received radiotherapy had significantly improved local control with minimal increase in treatment-related toxicity [2]

  • Local control of the disease did not translate to improvement in overall survival in the LAP07 study, there is evidence that in a subgroup of patients, local control could potentially translate to improvement in survival

Read more

Summary

Introduction

Pancreatic cancer, being the third leading cause of cancer-related deaths in the United States, is a devastating disease with an estimated 5-year overall survival of only 6% [1]. The recent LAP07 study showed no overall survival with chemotherapy alone, as compared to chemoradiotherapy after completion of induction chemotherapy in patients with locally advanced pancreatic cancer (LAPC); the study did demonstrate that those who received radiotherapy had significantly improved local control with minimal increase in treatment-related toxicity [2]. As the LAP07 study employed conventional fractionation that were delivered over 6 weeks, there is speculation that some patients may have developed metastatic disease during this period of time when they were not on optimal systemic treatment. Survival rates remained poor as these patients were predominantly dying of distant disease This provides further emphasis that these patients should have only limited time without systemic treatment

Radiobiological Reasoning for SBRT
Reirradiation
Proton Therapy
Carbon Ion Therapy
Findings
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call